Long-term shareholders of emerging ASX healthcare company Opthea Ltd (ASX: OPT) have endured a volatile 12 months. A little under a year ago, the Opthea share price was trading at a 52-week low of just $0.735. Then, in the space of a month, shares skyrocketed 465% to an all-time high price of $4.15.
In March, amid a wave of selloffs prompted by the global spread of COVID-19, the Opthea share price plunged all the way back down to just $1.25. Opthea shares have rallied significantly since then – at one point in early June they even looked set to push back up beyond $3.50. But then came yet another pullback, and as at the time of writing they are trading at $2.67.
What’s been driving the Opthea share price?
Opthea specialises in developing novel treatments for chronic eye diseases such as age-related macular degeneration (AMD). The initial steep rise in the share price back in August 2019 was driven by positive clinical trial results from a phase 2b study involving 366 patients suffering from “wet” AMD. Wet AMD is a condition caused by blood vessels leaking fluid into the macular resulting in blurred vision or persistent blind spots. According to Opthea, wet AMD is the leading cause of blindness for those aged over 50 across the developed world.
In the trial, Opthea’s OPT-302 treatment was shown to deliver statistically significant benefits versus the control group when used in combination with an existing wet AMD treatment called Lucentis. Opthea has stated that currently approximately 50% of wet AMD patients who use Lucentis will not experience significant gains in vision. And yet, in 2018 alone, sales of Lucentis totalled US $3.7 billion.
That trial was followed by positive results from a further phase 2a trial released just last month. This time, OPT-302 was used in combination with another therapy called Eylea in patients suffering from diabetic macular edema (DME). DME is a similar condition to wet AMD and occurs in people suffering the long-term effects of diabetes.
On Thursday, the company announced that the results of the trial will be presented at the upcoming American Society of Retina Specialists 2020 Annual Meeting. This gives Opthea significant international exposure, as over 3,000 retinal specialists from 63 countries are expected to attend the virtual meeting.
Should you invest?
Economic uncertainty caused by the COVID-19 global pandemic has made valuing growth stocks like Opthea incredibly difficult. Other emerging ASX healthcare companies like Medical Developments International Limited (ASX: MVP) and Polynovo Ltd (ASX: PNV) have also seen big swings in their share prices over the last 12 months as investors try to price in the longer-term impacts of the pandemic.
However, Opthea has continued to demonstrate that its treatments are not only effective but also address a debilitating condition affecting a significant portion of the population. Sales of Lucentis and Eylea show that this is a potentially lucrative market if Opthea can successfully commercialise its treatment.
The COVID-19 economy poses significant challenges to young companies. Supply-side logistical challenges may persist for months and funding will be harder to come by. However, for those willing to take on the risk, in my opinion an investment in Opthea has the potential to deliver significant long-term gains.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
More reading
- Why the Polynovo share price could climb in August
- Why this underperforming ASX healthcare company could still light up the market in 2020 and beyond
- Why the Opthea share price surged more than 20% today
- 4 exciting ASX biotech shares surging higher today
- 5 of the worst performing ASX shares from last week
Rhys Brock owns shares of Medical Developments International Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited and POLYNOVO FPO. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Why Opthea shares could offer big growth potential appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2ZV57Ib
Leave a Reply